Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jan 19;13(1):e0191389.
doi: 10.1371/journal.pone.0191389. eCollection 2018.

Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age

Ingrid J M Snijdewind  1 , Colette Smit  2 , Mieke H Godfried  3 , Rachel Bakker  4 , Jeannine F J B Nellen  3 , Vincent W V Jaddoe  4   5 , Elisabeth van Leeuwen  6 , Peter Reiss  2   3   7 , Eric A P Steegers  4   8 , Marchina E van der Ende  1
Affiliations
Observational Study

Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age

Ingrid J M Snijdewind et al. PLoS One. .

Abstract

Background: The benefits of combination anti-retroviral therapy (cART) in HIV-positive pregnant women (improved maternal health and prevention of mother to child transmission [pMTCT]) currently outweigh the adverse effects due to cART. As the variety of cART increases, however, the question arises as to which type of cART is safest for pregnant women and women of childbearing age. We studied the effect of timing and exposure to different classes of cART on adverse birth outcomes in a large HIV cohort in the Netherlands.

Materials and methods: We included singleton HEU infants registered in the ATHENA cohort from 1997 to 2015. Multivariate logistic regression analysis for single and multiple pregnancies was used to evaluate predictors of small for gestational age (SGA, birth weight <10th percentile for gestational age), low birth weight and preterm delivery.

Results: A total of 1392 children born to 1022 mothers were included. Of these, 331 (23.8%) children were SGA. Women starting cART before conception had an increased risk of having a SGA infant compared to women starting cART after conception (OR 1.35, 95% CI 1.03-1.77, p = 0.03). The risk for SGA was highest in women who started a protease inhibitor-(PI) based regimen prior to pregnancy, compared with women who initiated PI-based cART during pregnancy. While the association of preterm delivery and preconception cART was significant in univariate analysis, on multivariate analysis only a non-significant trend was observed (OR 1.39, 95% CI 0.94-1.92, p = 0.06) in women who had started cART before compared to after conception. In multivariate analysis, the risk of low birth weight (OR 1.34, 95% CI 0.94-1.92, p = 0.11) was not significantly increased in women who had started cART prior to conception compared to after conception.

Conclusion: In our cohort of pregnant HIV-positive women, the use of cART prior to conception, most notably a PI-based regimen, was associated with intrauterine growth restriction resulting in SGA. Data showed a non-significant trend in the risk of PTD associated with preconception use of cART compared to its use after conception. More studies are needed with regard to the mechanisms taking place in the placenta during fetal growth in pregnant HIV-positive women using cART. It will only be with this knowledge that we can begin to understand the potential impact of HIV and cART on the fetus, in order to be able to determine the optimal individualised drug regimen for HIV-infected women of childbearing age.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25(13):1611–8. Epub 2011/06/16. doi: 10.1097/QAD.0b013e3283493ed0 . - DOI - PubMed
    1. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010;201(7):1035–44. Epub 2010/03/04. doi: 10.1086/651232 ; PubMed Central PMCID: PMC2946359. - DOI - PMC - PubMed
    1. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–9. Epub 2004/12/04. doi: 00002030-200411190-00019 [pii]. . - PubMed
    1. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70. Epub 2002/06/14. doi: 10.1056/NEJMoa991159 [pii]. . - DOI - PubMed
    1. van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42. Epub 2011/08/17. doi: 1758-2652-14-42 [pii] doi: 10.1186/1758-2652-14-42 ; PubMed Central PMCID: PMC3163172. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

The authors received no specific funding for this work. The ATHENA database is supported by a grant from the Dutch Health Ministry and was set up and is maintained by Stichting HIV Monitoring. The funding sources of this study had no role in the study design, collection, data, or interpretation of the data, in the writing, or in the decision to submit the manuscript for publication.